Ulcers

Ulcers / 2011 / Article / Tab 2

Clinical Study

Use of Lozenges Containing Lactobacillus brevis CD2 in Recurrent Aphthous Stomatitis: A Double-Blind Placebo-Controlled Trial

Table 2

E Summary of laboratory parameters before and after administration of Lactobacillus Brevis CD2 or placebo lozenges.

L. brevis CD2PlaceboIntergroup comparison

Nitrite/Nitrate (μM)(T0)42.38 ± 4,5839.76 ± 5.08 𝑃 = . 1 4
(T1)7.5 ± 1.527.5 ± 3.5 𝑃 < . 0 1

PGE2 (ng ml−1)(T0)1.89 ± 0.21.77 ± 0.2 𝑃 = . 1 1
(T1)0.40 ± 0.051.02 ± 0.3 𝑃 < . 0 1

IFNγ (pg ml−1)(T0)32.25 ± 4.230.85 ± 4.2 𝑃 = . 3 6
(T1)9.57 ± 1.721.07 ± 2.9 𝑃 < . 0 1

T0: before treatment; T1: after treatment.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.